Le Lézard
Classified in: Health, Science and technology
Subject: MAT

Dr. Gary Nakhuda to Present Insights on Mosaic Embryo Transfer at CFAS Annual Meeting 2023


Dr. Gary Nakhuda, co-founder and co-director of Olive Fertility Centre, to provide a comprehensive review of embryonic mosaicism as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023.

VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.

Dr. Nakhuda's presentation, titled "Mosaic Embryo Transfer: Update on the Literature and the Canadian Experience," will provide a comprehensive review of embryonic mosaicism?a topic that often arises during Preimplantation Genetic Testing for Aneuploidy (PGT-A). The discussion will include an overview of the existing research on mosaicism and its implications in assisted reproduction. Furthermore, Dr. Nakhuda will discuss insights from Olive's extensive data and experience with PGT-A, adding an invaluable layer of real-world context to the discussion.

Mosaicism is a subject of ongoing debate within the field, particularly with the increased sensitivity of Next Generation Sequencing (NGS) technology. While NGS has improved the ability to detect mosaicism, questions persist about its impact on successful pregnancies.

Dr. Gary Nakhuda explains, "Embryonic mosaicism refers to the co-existence of cells with normal chromosome complements and others with apparent abnormalities. While the ability to detect mosaicism can be highly informative, we are recognizing that many of these embryos have the remarkable ability to apparently self-correct and may still result in healthy outcomes."

Nevertheless, debate persist regarding the transfer of mosaic embryos. This underscores the importance of facilitating patient access to genetic counseling resources, particularly when mosaicism emerges in PGT-A results.

Dr. Taylor, co-director of Olive Fertility Centre, emphasizes their commitment to patient-centered care grounded in scientific research: "Our dedication to advancing knowledge, exemplified by Dr. Nakhuda's work, empowers Olive to enhance our patients' chances of achieving pregnancy and delivering healthy babies."

Dr. Gary Nakhuda's presentation promises to be a significant contribution to the CFAS 2023 event, offering valuable insights that could shape the future of reproductive medicine. Olive Fertility Centre is honored to participate in the ongoing conversation and progress within the field, with a focus on scientific excellence and patient well-being.

Olive Fertility Centre (olivefertility.com) is one Canada's leading fertility centres with clinics in Vancouver, Surrey, Victoria, and Kelowna. We offer an award-winning IVF lab, personal care teams, and innovative programs including specialized genetic testing, egg freezing, and prenatal NIPT testing.

While the ability to detect mosaicism can be highly informative, we are recognizing that many of these embryos have the remarkable ability to apparently self-correct and may still result in healthy outcomes.

Media Contact

Mairi Campbell, Personae Concepts, 1 7788855300, [email protected], Personae.ca

 

SOURCE Personae Concepts


These press releases may also interest you

at 12:35
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by...

at 12:30
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...

at 12:05
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and...

at 12:05
Genmab A/S and AbbVie today announced new data from the ongoing phase 1/2 EPCOREtm NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall...

at 12:00
AbbVie and Genmab A/S announced today that adult patients with relapsed/refractory (R/R) follicular...

at 11:35
bluebird bio, Inc. ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel...



News published on and distributed by: